Limb Amputation Articles & Analysis
21 news found
VisionQuest Biomedical founder and CEO Peter Soliz (PhD) has just been awarded a $1 million Commercialization Readiness Pilot Program (CRP) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (part of the US National Institutes of Health) for his work on early detection of DPN. With the support of this grant, Dr. Soliz will develop a commercial prototype and seek FDA ...
We believe the REVA absorbable scaffold has the potential to reduce limb amputations, and possibly save lives.” In addition to the MOTIV scaffold, REVA is in the final development stages for their TyroSphere embolic bead platform. ...
Severe peripheral vascular disease (PVD) is caused by the formation of blockages in arteries, which reduces blood supply to the brain, heart, kidneys and limbs causing strokes, heart attacks, kidney failure and limb amputations. ...
Safety: Freedom from device- and procedure-related death through 30 days and a composite of major target limb amputation and CD-TVR @ 12 months. Miquel Craven-Bartle Capella CEO of Cardionovum® commented: “We are very happy with this first enrollment. ...
ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double-blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation. ...
ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation. ...
ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation. ...
“Diabetic ulcers are the leading cause of non-traumatic lower limb amputations, and dramatically increase patient mortality. Despite a huge unmet need, no pharmacological wound healing product has been approved for more than 10 years,” said Thomas Wirth, CSO of Aurealis Therapeutics. ...
ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation. ...
ACP-01 is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation. ...
SOMERVILLE, Mass., January 18, 2022 — Podimetrics, a virtual care support company dedicated to preventing costly and deadly diabetic amputations, today announced results from its latest research, which compared the health of individuals during and after periods of diabetic foot ulceration — open sores or wounds on the foot, which commonly occur among those with ...
Method: Retrospective observational study on 4,578 Veterans hospitalized for LLA and discharged 2003- 2004, looking at time to all-cause mortality from the amputation surgical date up to the 3 yr anniversary. Results: 1,300 (28.4%) persons received a prescription for a prosthetic limb within 1 yr after the surgical amputation. ...
The combination of ACP-01, an autologous angiogenic cell precursor that has demonstrated improvement of angiogenesis in the heart and limbs of individuals who suffer from ischemia, and cell transplants from human islets or stem cells, hold huge promise in the treatment of diabetes. ...
ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation. ...
ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation. ...
ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation. ...
In the United States alone, there are nearly two million lower limb amputees, with 160,000 new amputations occurring annually. Chronic post-amputation pain is a significant unmet medical need, as existing treatment options are limited, and consist primarily of opioids and gabapentinoids. Chronic post-amputation pain is ...
Research conducted by Kaiser Permanente also found once-daily remote temperature monitoring with Podimetrics decreased overall resource utilization SOMERVILLE, Mass., October 14, 2020 — Podimetrics, a virtual care management company with the leading solution to help prevent costly and deadly diabetic amputations, today announced results from its latest study of patients ...
This buildup, or plaque, reduces or blocks blood flow and is the leading cause of limb amputations. More than half of patients who receive an amputation die within five years, a figure that is higher than the mortality rates for breast, colon and prostate cancers. ...
PAD leads to narrowing of blood vessels and reduced oxygenated blood flow that can result in amputation of an extremity. “Acquiring the CE Mark is a major milestone our development team and regulatory partners have worked hard to achieve,” said Ben Hwang, Ph.D., Profusa’s chairman and CEO. ...